GLP-1s for Neurodegenerative Disease

GLP-1 receptor agonists (GLP-1 RAs) are a class of drugs that mimic glucagon-like peptide-1, initially developed for type 2 diabetes and later approved for obesity. They improve glycaemic control and weight and have cardiovascular benefits. Mechanistically, GLP-1 receptors are expressed in the brain as well as peripheral tissues; agonists can cross the blood–brain barrier or reach central targets, where they have been shown in preclinical and early clinical work to reduce neuroinflammation and support clearance of aggregated proteins (e.g. amyloid, alpha-synuclein) implicated in Alzheimer’s and Parkinson’s. Several GLP-1 RAs are in clinical trials for neurodegenerative and cognitive outcomes.

The repurposing addresses a major unmet need: more than 55 million people live with dementia globally, and disease-modifying therapies for Alzheimer’s and Parkinson’s remain limited. If GLP-1 RAs delay progression or preserve function, the impact would extend to caregivers and health systems. Observational and trial data are accumulating; results from large phase 3 studies will determine whether the signal translates into approved indications. Safety and tolerability profiles are reasonably well understood from diabetes and obesity use, though long-term effects in neurological populations may need further study.

Outcome measures, trial design, and subgroup identification are active areas of research. If positive, GLP-1 RAs could become part of the toolkit for neurodegenerative disease, alongside other pharmacological and non-pharmacological interventions. The story illustrates how drugs developed for one indication can find new utility when mechanisms are understood across organ systems.